{"id":545881,"date":"2021-06-02T18:58:01","date_gmt":"2021-06-02T18:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=545881"},"modified":"2021-06-02T18:58:01","modified_gmt":"2021-06-02T18:58:01","slug":"immune-thrombocytopenia-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-immunomedics-oscotech-bioverativ-novartis-pfizer-and-many-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/immune-thrombocytopenia-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-immunomedics-oscotech-bioverativ-novartis-pfizer-and-many-others_545881.html","title":{"rendered":"Immune Thrombocytopenia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Immunomedics, Oscotech, Bioverativ, Novartis, Pfizer and Many Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1622608001.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Immune Thrombocytopenia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Immunomedics, Oscotech, Bioverativ, Novartis, Pfizer and Many Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1622608001.jpeg\" alt=\"Immune Thrombocytopenia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Immunomedics, Oscotech, Bioverativ, Novartis, Pfizer and Many Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Immune Thrombocytopenia Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Immune thrombocytopenia<\/strong> or ITP is a bleeding disorder. In ITP, the blood doesn&#8217;t clot as it should. This is due to a low number of blood cell fragments called platelets or thrombocytes. People who have ITP often have purple bruises called purpura. These bruises appear on the skin or mucous membranes. Bleeding from small blood vessels under the skin causes purpura. People who have ITP also may have bleeding that causes tiny red or purple dots on the skin. These pinpoint-sized dots are called petechiae. Petechiae may look like a rash.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,<strong>&nbsp;&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/immune-thrombocytopenia-itp-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Immune Thrombocytopenia Pipeline<\/a> Insights, 2021,&rdquo;&nbsp;<\/strong>report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Immune Thrombocytopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/immune-thrombocytopenia-itp-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/immune-thrombocytopenia-itp-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <\/strong><strong>Immune Thrombocytopenia Companies<\/strong><strong> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Argenx<\/li>\n<li>HanAll Biopharma<\/li>\n<li>Eris Lifesciences<\/li>\n<li>Momenta Pharmaceuticals<\/li>\n<li>Taiho Pharmaceutical<\/li>\n<li>Takeda<\/li>\n<li>UCB Pharma<\/li>\n<li>Immunomedics<\/li>\n<li>Oscotech<\/li>\n<li>Bioverativ, a Sanofi company<\/li>\n<li>Novartis<\/li>\n<li>Pfizer<\/li>\n<li>Kissei Pharmaceutical Co., Ltd.<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/immune-thrombocytopenia-itp-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/immune-thrombocytopenia-itp-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s <\/strong><strong>Immune Thrombocytopenia report<\/strong><strong> covers around 50+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase II and Phase II\/III)<\/li>\n<li>Mid-stage products (Phase II and Phase II\/III)<\/li>\n<li>Early-stage products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/immune-thrombocytopenia-itp-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr%27\">Immune Thrombocytopenia Key Products<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Efgartigimod<\/li>\n<li>Rozanolixizumab<\/li>\n<li>TAK-079<\/li>\n<li>HL161<\/li>\n<li>Romiplostim biosimilar<\/li>\n<li>R788<\/li>\n<li>M254<\/li>\n<li>Eltrombopag<\/li>\n<li>PRN1008<\/li>\n<li>HMPL-523<\/li>\n<li>SKI-O-703<\/li>\n<li>HBM9161<\/li>\n<li>BIVV009<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/immune-thrombocytopenia-itp-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/immune-thrombocytopenia-itp-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current <\/strong><strong>Immune Thrombocytopenia Treatment<\/strong><strong> Scenario and<\/strong><strong> Immune Thrombocytopenia Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Immune Thrombocytopenia drugs?<\/li>\n<li>How many Immune Thrombocytopenia drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Immune Thrombocytopenia?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Immune Thrombocytopenia therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Immune Thrombocytopenia and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Immune thrombocytopenia: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Immune thrombocytopenia &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">&bull; Immune thrombocytopenia companies&rsquo; collaborations, Licensing, Acquisition -Deal Value Trends<\/p>\n<p style=\"text-align: justify;\">Immune thrombocytopenia Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Rozanolixizumab (UCB7665): UCB<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">BIVV-020: Bioverativ<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I\/II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">M 254: Momenta Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Preclinical\/Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">CNP-105: Cour Pharmaceutical Development<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Immune thrombocytopenia Key Companies<\/p>\n<p style=\"text-align: justify;\">Immune thrombocytopenia Key Products<\/p>\n<p style=\"text-align: justify;\">Immune thrombocytopenia- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Immune thrombocytopenia- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Immune thrombocytopenia- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Immune thrombocytopenia Analyst Views<\/p>\n<p style=\"text-align: justify;\">Immune thrombocytopenia Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/immune-thrombocytopenia-itp-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=immune-thrombocytopenia-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-immunomedics-oscotech-bioverativ-novartis-pfizer-and-many-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/immune-thrombocytopenia-itp-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/immune-thrombocytopenia-itp-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/immune-thrombocytopenia-itp-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=immune-thrombocytopenia-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-immunomedics-oscotech-bioverativ-novartis-pfizer-and-many-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Immune Thrombocytopenia Pipeline Immune thrombocytopenia or ITP is a bleeding disorder. In ITP, the blood doesn&#8217;t clot as it should. This is due to a low number of blood cell fragments called platelets or thrombocytes. People who have ITP often &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/immune-thrombocytopenia-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-immunomedics-oscotech-bioverativ-novartis-pfizer-and-many-others_545881.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-545881","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=545881"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545881\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=545881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=545881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=545881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}